Pharmacotherapy of urolithiasis: Evidence from clinical trials

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies.

Original languageEnglish (US)
Pages (from-to)385-392
Number of pages8
JournalKidney International
Volume79
Issue number4
DOIs
StatePublished - Feb 2011

Fingerprint

Urolithiasis
Physical Chemistry
Clinical Trials
Hypercalciuria
Drug Therapy
Biochemistry
Randomized Controlled Trials
Economics
Health
Therapeutics
Pharmaceutical Preparations
Clinical Studies

Keywords

  • clinical trial
  • hypercalciuria
  • kidney disease: improving global outcomes
  • kidney stones
  • pathophysiology of renal disease and progression

ASJC Scopus subject areas

  • Nephrology

Cite this

Pharmacotherapy of urolithiasis : Evidence from clinical trials. / Moe, Orson W; Pearle, Margaret S; Sakhaee, Khashayar.

In: Kidney International, Vol. 79, No. 4, 02.2011, p. 385-392.

Research output: Contribution to journalArticle

@article{2473819748604073bf48e809cd1e48e9,
title = "Pharmacotherapy of urolithiasis: Evidence from clinical trials",
abstract = "Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies.",
keywords = "clinical trial, hypercalciuria, kidney disease: improving global outcomes, kidney stones, pathophysiology of renal disease and progression",
author = "Moe, {Orson W} and Pearle, {Margaret S} and Khashayar Sakhaee",
year = "2011",
month = "2",
doi = "10.1038/ki.2010.389",
language = "English (US)",
volume = "79",
pages = "385--392",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Pharmacotherapy of urolithiasis

T2 - Evidence from clinical trials

AU - Moe, Orson W

AU - Pearle, Margaret S

AU - Sakhaee, Khashayar

PY - 2011/2

Y1 - 2011/2

N2 - Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies.

AB - Urolithiasis is a worldwide problem with significant health and economic burdens. Medical therapy that alters the course of stone disease has enormous medical and financial impact. Urolithiasis is a final manifestation of a broad range of etiologies and pathogenesis. The modest progress in understanding the pathophysiology has hampered successful development of targeted therapy. Current regimens are based mostly on rational alteration of urinary biochemistry and physical chemistry to lower the risk of precipitation. In terms of pharmacotherapy, there are drugs to successfully improve hypercalciuria, hypocitraturia, aciduria, hyperuricosuria, and hypercystinuria. These agents have been proven to be effective in randomized controlled trials in improving urinary biochemical and physicochemical risk factors, as well as clinical outcomes. Although our current regimens have clearly improved the management and lives of stone formers, there are still clearly identifiable immense voids in the knowledge of pathophysiology of stone disease that can be filled with combined basic science and clinical studies.

KW - clinical trial

KW - hypercalciuria

KW - kidney disease: improving global outcomes

KW - kidney stones

KW - pathophysiology of renal disease and progression

UR - http://www.scopus.com/inward/record.url?scp=79551529059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551529059&partnerID=8YFLogxK

U2 - 10.1038/ki.2010.389

DO - 10.1038/ki.2010.389

M3 - Article

C2 - 20927039

AN - SCOPUS:79551529059

VL - 79

SP - 385

EP - 392

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -